Action Vivoryon Therapeutics Nv - 0R3M

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

4,71

Prix Achat

0,00

Prix Vente

0,00

Volume échangé

0,00 Fourchette du Jour 0,00

4,71 Plage de 52 semaines 4,71

Cap du marché

Clôture Veille

4,71

Ouverture

Dernière Transaction

2.02

(O)

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

4 288

Actions en circulation

0,00

Rendement du Dividende

Ratio Cours sur Bénéfices

0,00

Bénéfice par action (BPA)

Chiffre d'affairess

-3,62M

Bénéfice net

-28,34M

Secteur

Biological Pds,ex Diagnstics

Industrie

Biological Pds,ex Diagnstics

Site Web

www.vivoryon.com

Siège social

Halle, Deu

Fondé

Vivoryon Therapeutics Nv est coté dans le secteur Biological Pds,ex Diagnstics de la London Stock Exchange avec le ticker 0R3M. Le dernier cours de clôture d'Vivoryon Therapeutics Nv était de 4,71 €. Au cours de la dernière année, les actions de Vivoryon Therapeutics Nv ont été négociées dans une fourchette de prix de 4,71 € à 4,71 €.

Vivoryon Therapeutics Nv compte actuellement 0 actions en circulation.

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function Vivoryon Therapeutics N.V. Presents Topline Phase...

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024 Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress...

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of...

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon...

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY;...

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease Vivoryon Therapeutics N.V...

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and...

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024 Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial...

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in...

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on...

Période	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	4.71	4.71	4.71	1118	4.71	DE
4	4.71	4.71	4.71	1374	4.71	DE
12	4.71	4.71	4.71	4288	4.71	DE
26	4.71	4.71	4.71	5526	4.71	DE
52	4.71	4.71	4.71	12311	4.71	DE
156	4.71	4.71	4.71	6012	4.71	DE
260	4.71	4.71	4.71	4310	4.71	DE

0R3M - Frequently Asked Questions (FAQ)

What is the current Vivoryon Therapeutics Nv share price?

The current share price of Vivoryon Therapeutics Nv is 4,71 €

What is the 1 year trading range for Vivoryon Therapeutics Nv share price?

Vivoryon Therapeutics Nv has traded in the range of 4,71 € to 4,71 € during the past year

What is the reporting currency for Vivoryon Therapeutics Nv?

Vivoryon Therapeutics Nv reports financial results in EUR

What is the latest annual turnover for Vivoryon Therapeutics Nv?

The latest annual turnover of Vivoryon Therapeutics Nv is EUR -3,62M

What is the latest annual profit for Vivoryon Therapeutics Nv?

The latest annual profit of Vivoryon Therapeutics Nv is EUR -28,34M

What is the registered address of Vivoryon Therapeutics Nv?

The registered address for Vivoryon Therapeutics Nv is WEINBERGWEG 22, HALLE, 06120

What is the Vivoryon Therapeutics Nv website address?

The website address for Vivoryon Therapeutics Nv is www.vivoryon.com

Which industry sector does Vivoryon Therapeutics Nv operate in?

Vivoryon Therapeutics Nv operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
WSLWorldsec Ld	2,00p (60,00%)	105,37k
BLUBlue Star Capital Plc	12,00p (45,45%)	1,54M
NTQEnteq Technologies Plc	1,40p (40,00%)	19,81M
BANKFiinu Plc	10,25p (36,67%)	12,95M
TIRTiger Royalties And Investments Plc	0,16p (28,00%)	139,07M
PODPPod Point Group Holdings Plc	10,88p (-35,20%)	6,83M
PALMPanther Metals Plc	53,50p (-35,15%)	226,06k
NOGNostrum Oil & Gas Plc	2,51p (-23,82%)	117,6k
ADMEAdm Energy Plc	0,175p (-22,22%)	1,19M
PRDPredator Oil & Gas Holdings Plc	5,85p (-20,95%)	5,72M
NTVONativo Resources Plc	0,0021p (10,53%)	844,9M
TRPTower Resources Plc	0,0305p (-1,61%)	507,22M
PREMPremier African Minerals Limited	0,027p (-3,57%)	504,81M
SYMESupply@me Capital Plc	0,003p (-13,04%)	461,39M
ORCPOracle Power Plc	0,016p (-5,88%)	308,68M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Vivoryon Therapeutics Nv (0R3M) Cours

Vivoryon Therapeutics Nv (0R3M)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Vivoryon Therapeutics Nv

0R3M Dernières nouvelles

0R3M - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application